Los Angeles Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Los Angeles Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.73K	Hold	257	–	–	﹤0.01%	2268
2026 Q1	$1.98K	Sell	257 -2,106	-89%	-$15.4K	﹤0.01%	2289
2025 Q4	$22.8K	Buy	+2,363	New	+$25.5K	﹤0.01%	1833
2025 Q1	–	Sell	-23,808	Closed	-$404K	–	1087
2024 Q4	$404K	Buy	23,808 +375	+2%	+$7.06K	﹤0.01%	861
2024 Q3	$544K	Buy	+23,433	New	+$501K	﹤0.01%	842
2023 Q3	–	Sell	-10,572	Closed	-$303K	–	1115
2023 Q2	$303K	Sell	10,572 -1,750	-14%	-$47.6K	﹤0.01%	1000
2023 Q1	$295K	Hold	12,322	–	–	﹤0.01%	1011
2022 Q4	$209K	Hold	12,322	–	–	﹤0.01%	1135
2022 Q3	$183K	Hold	12,322	–	–	﹤0.01%	1177
2022 Q2	$194K	Sell	12,322 -47,308	-79%	-$928K	﹤0.01%	1272
2022 Q1	$1.61M	Buy	+59,630	New	+$1.52M	0.01%	597
2021 Q3	–	Sell	-8,357	Closed	-$283K	–	1469
2021 Q2	$283K	Buy	+8,357	New	+$283K	﹤0.01%	1410

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Los Angeles Capital Management's ARCT Position: Q2 2026 in Review

Los Angeles Capital Management held its Arcturus Therapeutics (ARCT) position steady in Q2 2026 at 257 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #2268.

Los Angeles Capital Management first reported a position in ARCT in Q2 2021 and has held it in 12 quarters since. The position peaked at $1.61M in Q1 2022. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Los Angeles Capital Management held 257 shares of Arcturus Therapeutics worth $1.73K as of Q2 2026.
Los Angeles Capital Management left its Arcturus Therapeutics share count unchanged in Q2 2026.
Arcturus Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2268 holding.
Los Angeles Capital Management first reported a position in Arcturus Therapeutics in Q2 2021 and has held it in 12 quarters since.
Los Angeles Capital Management's Arcturus Therapeutics position peaked at $1.61M in Q1 2022.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.